Core Insights - Lexaria Bioscience Corp. has released additional data from its Phase 1b clinical study GLP-1-H24-4, which focuses on the efficacy of its DehydraTECH™ technology compared to Rybelsus® [1][2] Secondary Efficacy Parameters - At week 16, the DHT arms showed no statistically significant differences compared to the Rybelsus® control in mean fasting glucose, cholesterol, and LDL cholesterol [3] Body Composition - The DHT-semaglutide arm showed a modest reduction in fat mass of -1.08 kg and total mass of -1.40 kg, while the Rybelsus® control arm achieved greater reductions of -3.55 kg in fat mass and -5.36 kg in total mass, with a higher reduction in lean mass of -1.72 kg [4] Blood Pressure Analyses - The DHT-CBD arm achieved significant reductions in blood pressure, with a mean change of -4.6 mmHg in systolic and -4.0 mmHg in diastolic blood pressure at week 4 [5][6] Pharmacokinetic Exploratory Analyses - Plasma CBD concentrations were quantifiable through week 16 in the DHT-CBD arms, while semaglutide concentrations were not quantifiable due to assay issues, although preliminary tests indicated measurable levels [8] Health Survey Results - Participants in the DHT-semaglutide arm reported mean improvements of over 5 points in physical components and over 3 points in mental components of the SF-36 health survey, compared to modest improvements in the Rybelsus® control arm [9][10] Overall Conclusions and Next Steps - The study met its primary endpoint, demonstrating good safety and tolerability of all DHT test articles, with positive findings across various parameters compared to Rybelsus® [11] Future Plans - Lexaria plans to pursue further clinical testing with a DHT + SNAC + semaglutide composition and is in discussions with a pharmaceutical company regarding the dataset from the study [15][17][18]

Core Insights - Softbank has completed its $40 billion investment commitment to OpenAI, with a final investment of $22 billion to $22.5 billion sent last week [1] - The total investment includes a previous $10 billion syndicated and $8 billion directly invested in OpenAI [1] - The investment values OpenAI at a pre-money valuation of $260 billion [1] Funding Details - The funding will be disbursed over a 12 to 24 month period [2] - Part of the investment is intended to support OpenAI's artificial intelligence infrastructure through the Stargate joint venture with Oracle and Softbank [2]

Core Viewpoint - Air China and its subsidiary have signed an agreement with Airbus to purchase 60 A320NEO jets, valued at approximately $9.5 billion at list prices [1] Company Summary - Air China is expanding its fleet by acquiring 60 A320NEO jets from Airbus [1] - The total value of the deal is around $9.5 billion, indicating a significant investment in modernizing and expanding its aircraft capabilities [1] Industry Summary - The agreement reflects ongoing demand for new aircraft in the aviation industry, particularly for fuel-efficient models like the A320NEO [1] - This purchase may enhance Air China's competitive position in the market as airlines increasingly focus on sustainability and operational efficiency [1]

SoftBank Group has completed its $40 billion investment in OpenAI, CNBC reported on Tuesday, citing people familiar with the matter. ...

Lexaria Bioscience Corp. (NASDAQ:LEXX) on Tuesday provided an update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, focusing on 4 DehydraTECH ( DHT) study arms relative to the Novo Nordisk A/S‘ (NYSE:NVO) Rybelsus (semaglutide) control study arm.“We are extremely pleased to not only have successfully achieved our primary endpoint,” stated Richard Christopher, CEO of Lexaria, “but to have also demonstrated obvious superiority in reducing unwanted side effects by as much ...

Core Insights - Lexaria Bioscience Corp. has successfully achieved its primary endpoint in the Phase 1b study GLP-1-H24-4, demonstrating significant efficacy in reducing unwanted side effects compared to Rybelsus® [2][13] - The company raised a total of $7.5 million through financing activities, which will support new development opportunities throughout 2026 [2][18] - The study results indicate that DehydraTECH-semaglutide reduced overall side effects by 48% and gastrointestinal side effects by 55% compared to Rybelsus® [4][6] Study Results - All four DehydraTECH (DHT) test articles were found to be safe and well-tolerated, meeting the primary endpoint objective [3][13] - The total adverse events (AEs) for DHT-semaglutide were reduced by 47.9% compared to Rybelsus®, with a statistically significant reduction in gastrointestinal AEs [6][10] - The study included 126 participants, focusing on safety and tolerability, with DHT-semaglutide showing the best performance among the tested formulations [19] Efficacy Assessments - The primary efficacy endpoint of HbA1c reduction showed comparable performance between DHT-semaglutide and Rybelsus®, with no statistically significant difference [10][11] - Bodyweight reduction was more pronounced in the Rybelsus® control arm compared to all DHT arms, raising questions about the differing results [11][12] - The study's findings suggest that even small reductions in HbA1c can improve cardiovascular outcomes in overweight or obese individuals [10] Future Directions - Lexaria plans to investigate the DHT-semaglutide formulation further, potentially incorporating salcaprozate sodium (SNAC) in future studies [14][15] - The company aims to relay the study dataset to its pharmaceutical partner under a Material Transfer Agreement, which has been extended to April 30, 2026 [16][17] - Additional non-primary endpoint results are expected to be released soon, providing further insights into the study's findings [20]

 Kelowna, British Columbia – December 16, 2025 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 2,661,600 shares of its common stock, par value $0.001 per share, at a purchase price of $1.315 per share. In addition, in a concurrent private placement, the Company issued unregiste ...

Core Viewpoint - Lexaria Bioscience Corp. has announced a definitive agreement for a registered direct offering of 2,661,600 shares of common stock at a price of $1.315 per share, along with a concurrent private placement of unregistered warrants to purchase the same number of shares at an exercise price of $1.19 per share [1][2]. Group 1: Offering Details - The total gross proceeds from the offering are expected to be approximately $3.5 million before deducting fees and expenses [2]. - The offering is being conducted under a "shelf" registration statement that was declared effective by the SEC on January 30, 2025 [3]. - The warrants will be immediately exercisable and will expire five years from the effectiveness of the resale registration statement [1]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to advance research and development efforts, fund working capital, and cover other general corporate purposes [2]. Group 3: Company Background - Lexaria Bioscience Corp. specializes in drug delivery platforms, particularly its patented DehydraTECH™ technology, which enhances the absorption of drugs through oral delivery [6][7]. - The company holds a robust intellectual property portfolio with 56 patents granted and additional patents pending worldwide [7].

Core Viewpoint - The company has announced the acquisition of Arthrosi Therapeutics, pending regulatory clearance, which will enhance its gout treatment pipeline with the addition of Pozdeutinurad AR882, a next-generation URAT1 inhibitor [1][3]. Group 1: Acquisition Details - The acquisition aims to integrate Pozdeutinurad AR882 into the company's gout pipeline, which is expected to provide a novel best-in-class therapy for patients suffering from progressive gout [3][4]. - Pozdeutinurad has demonstrated clinically meaningful efficacy and a strong safety profile in several large Phase II trials, indicating its potential as a significant advancement in gout treatment [4]. Group 2: Strategic Rationale - The strategic rationale for the acquisition includes the opportunity to leverage Pozdeutinurad's unique properties as a once-daily oral medication, which could address unmet needs in the gout treatment market [4].

Revenue and Growth - Lexaria's total revenue for fiscal year 2025 increased by $241,645, or 52%, to $705,923 from $464,278 in fiscal year 2024[176] - Licensing revenue grew by $238,010, or 52%, to $696,000 in fiscal year 2025 compared to $457,990 in fiscal year 2024[176] Expenses and Losses - Research and development expenditures increased by $5,878,192, or 249%, to $8,238,757 in fiscal year 2025 from $2,360,565 in fiscal year 2024[178] - The net loss from operations increased by $6,102,780 to $11,911,434 for the year ended August 31, 2025, compared to $5,808,654 for the year ended August 31, 2024[174] - General and administrative expenses increased by $493,162, or 13%, to $4,345,183 in fiscal year 2025 from $3,852,021 in fiscal year 2024[183] - Other Income/(Loss) for fiscal year 2025 decreased by $24,827, or 45%, resulting in a loss of $30,697, down from a loss of $55,524 in fiscal year 2024[186] - The Company has accumulated net losses of $63.5 million since entering the bioscience sector, with approximately $11.9 million and $5.8 million incurred in the past two fiscal years[187] Cash Flow and Financial Position - As of August 31, 2025, the Company had cash on hand of approximately $1.8 million to settle $1.5 million in current liabilities, raising substantial doubt about its ability to continue as a going concern[193] - The Company's working capital decreased by approximately $4.8 million, with current assets at $3,468,345 and current liabilities at $1,493,463 as of August 31, 2025[195] - Net cash used in operating activities was approximately $10.5 million for the year ended August 31, 2025, compared to $5.0 million during the same period in 2024, primarily due to an increase in net loss[197] - Net cash provided by financing activities totaled approximately $6.0 million from the sale of common shares during the fiscal year[199] Strategic Initiatives and Future Outlook - Lexaria anticipates a decrease in revenue from technology licensing in fiscal 2026 due to the expiration of its license agreement with Premier[177] - The company is exploring equity financing arrangements and strategic corporate partnerships to support its drug investigations[173] - The Company intends to form industry partnerships for later stage clinical development, which is expected to be a multi-year process[188] Research and Development - Lexaria completed two human pilot studies and an Australian clinical trial investigating DehydraTECH infused GLP-1, GIP, and CBD formulations during the fiscal year[169] - The company was granted a total of six new patents during fiscal 2025, including patents for treating epilepsy and diabetes[165] Share Issuance - The Company issued 2,000,000 shares of common stock at $1.00 each in a registered direct offering, generating net proceeds of $1.7 million[189] - On September 26, 2025, the Company agreed to sell 2,666,667 shares of common stock at a purchase price of $1.50 per share, resulting in net proceeds of $3.5 million[191] Impairment and Losses - The Company recognized an impairment loss of $247,364 related to abandoned patent applications for the year ended August 31, 2025, compared to $57,836 for the year ended August 31, 2024[185]